Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...
Using AI and Australia's supercomputing infrastructure, researchers mapped 94 million craters on Mars, transforming planetary ...